Therapeutic effect of Hugan tablet combined with tenofovir disoproxil on chronic hepatitis B patients and its influence on cytokines and vascular endothelial function / 中国基层医药

ABSTRACT

Objective:To investigate the therapeutic effect of Hugan tablet combined with tenofovir disoproxil on patients with chronic hepatitis B and its influence on the cellular inflammatory factors and vascular endothelial function.Methods:From January 2017 to December 2018, 100 patients with chronic hepatitis B admitted to Dongyang People's Hospital were randomly divided into observation group (50 cases) and control group (50 cases) according to the random digital table method.The control group was treated with tenofovir disoproxil, while the observation group was treated with Hugan tablet on the basis of the control group.The course of treatment in both two groups was 48 weeks.The therapeutic effect and HBV-DNA negative transformation of the two groups were compared, and the changes of liver function, cytokines and vascular endothelial function before and after treatment were compared.Results:The total effective rate of the observation group (92.00%) was higher than that of the control group (72.00%) (χ 2=6.775, P<0.05). The negative rate of HBV-DNA in the observation group (68.00%) was higher than that in the control group (50.00%) (χ 2=4.105, P<0.05). The serum AST[(51.28±7.29)U/L], TBIL[(16.69±3.18)μmol/L] and ALT[(48.93±7.87)U/L] in the observation group were lower than those in the control group [(81.32±14.25)U/L, (24.31±5.47)μmol/L and (94.34±18.37)U/L] ( t=13.271, 8.516 and 16.067, all P<0.05). The serum IL-2 [(178.38±19.98)ng/L] in the observation group was higher than that in the control group [(131.07±13.42)ng/L], while the serum IL-4 [(38.19±6.19)ng/L] and IL-10 [(48.93±7.87)ng/L] in the observation group were lower than those in the control group [(54.76±5.84)ng/L and (94.34±18.37)ng/L] ( t=13.899, 13.768, 16.067, all P<0.05). The serum VEGF[(101.32±8.78)ng/L] and ET-1[(34.82±2.97)ng/L] in the observation group were lower than those in the control group [(127.90±15.46)ng/L and (38.98±3.41)ng/L] ( t=10.571, 6.505, all P<0.05). Conclusion:Hugan tablet combined with tenofovir disoproxil has good therapeutic effect on patients with chronic hepatitis B, which can improve the liver function, reduce the inflammatory reaction of cells and improve the vascular endothelial function.